logo
  

Endo To Pay $50 Mln To Settle Opioid Claims By New York State And Its Counties

Endo International plc (ENDP) said that it has agreed to pay $50 million to settle lawsuits by New York state, Suffolk and Nassau counties, related to marketing and sale of prescription opioid medications.

ENDP closed Thursday regular trading at $2.10, down $0.01 or 0.47%. But in the after-hours trade, the stock gained $0.38 or 18.10%.

As a result of the settlement, Endo have been severed from an ongoing trial in lawsuits by the New York state and the two counties.

Endo noted that the settlement includes no admission of wrongdoing, fault or liability of any kind by Endo or its subsidiaries, and the settlement value should not be extrapolated to any other opioid-related cases or claims.

Endo noted that litigation of the remaining opioid claims is ongoing, but the company is focused on its primary goal of achieving a global settlement.

Endo is also currently exploring other strategic alternatives and may seek to implement one or more of those alternatives in the event it is unable to achieve a global settlement.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Rancho Cordova, California-based E-filliate Inc. is recalling about 301,800 units of DEWALT wireless earphones citing burn and fire risks, the U.S. Consumer Product Safety Commission said. The recall involves DEWALT Jobsite Pro Wireless Earphones, which have a black and yellow neckband with wired earbuds. According to the agency, the wireless earphones can overheat while charging or in use. The five-day holiday shopping period from Thanksgiving Day through Cyber Monday saw about 180 million Americans making in-store and online purchases, according to the National Retail Federation's Annual Thanksgiving Weekend Consumer Survey, conducted by Prosper Insights & Analytics. The shoppers spent an average of $301.27 on holiday-related purchases such as gifts, décor, apparel and toys. Biopharmaceutical company Immunome, Inc. (IMNM) announced Wednesday that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529). Based upon structural mapping of those mutations and activity against previous and current CDC variants of concern,...
Follow RTT